Challenges in the Trafficking in Fraudulent MedicinesVienna, 14 & 15 February 2013

Bernard Frahi, VP Corporate Economic Security – Sanofi

| 1UNODC CONFERENCE

A public health issue…

Patient safety is the essence of the pharmaceutical

industry

UNODC CONFERENCE | 2

… Under threat from faked production

UNODC CONFERENCE | 3

| 4

Various terminologies for a unique public health issue

“Counterfeit

medicines”(WHO, 1992)

UNODC CONFERENCE

Strategy aligned to patients’ protection

| 5UNODC CONFERENCE

Do we have the real picture of the Counterfeit medicines situation?

Sampling analyzed locally by National Agencies and not transmitted to Pharma companies

Local enforcement

bodies,

WCO, INTERPOL

Key playersAvailable Data

Invisible business for law enforcement authorities

Sampling received at Central Laboratory, Suspicious (seizures, investigation, cyber …) and Market Surveys

| 6UNODC CONFERENCE

Unknown Data

&

PSI

Fake drugs: transnational criminal networks

Clandestine labs dismantled in 2010

Clandestine labs dismantled in 2011

Clandestine labs dismantled in 2012

11

3

11

| 7UNODC CONFERENCE

Main ports of discharge on the continent

Interpol

. Cobra : West (2011)

. Mamba III : East (2010)

WCO Operations incl. Sanofi

WCO/ IPM Implementation

CESD Enquiries / 2012

LOW

HIGH

MEDIUM

COUNTERFEIT RISK

Flows of falsified medicines

PSI report 2011 :

Africa is the last continent affected by counterfeiting

according PSI. PSI recorded 64 incidents and 3 arrests.

� Lack of information

Counterfeiting in Africa

ALGERIA

MOROCCO

TUNISIA

LYBIA EGYPT

SUDAN

ANGOLA

DEMOCRATIC REPUBLIC

OF CONGO

CONGO

MALI

MAURITANIA

BENIN

TOGO

SOUTH AFRICA

NIGER

NIGERIA

CHAD

MADAGASCAR

ETHIOPIA

KENYA

SOMALIA

DJIBOUTI

TANZANIA

NAMIBIA

BOTSWANA

ZIMBABWE

ZAMBIA

MOZAMBIQUE

MALAWI

CENTRAL AFRICAN

REPUBLIC

SENEGAL

GHANA

IVORY

COAST

LIBERIA

SIERRA LEONE

GUINEAGUINEA

BISSAU

GAMBIA

WESTERN SAHARA

CAMEROON

UGANDA

RWANDA

BURUNDI

BURKINA FASO

ERITREA

CORMOROS

EQUATORIAL

GUINEA

GABON

LESOTHO

SWAZILAND

Max 55 (2010)

Morocco

Fred 60 (2011)

Benin

Vice Grips 2 (2012)

Togo

Harmattan (2011)

Cameroon

IPR Seminar (2012)

Kenya

Eastern Gate (2012)

Djibouti

UNODC CONFERENCE | 8

Partnering to combat the threat of fake medicines

UNODC CONFERENCE | 9

A broadened partnership

| 10

PharmaFederations

Health Organizations

Other Organizations

Organizations & Specialized Agencies

UNODC CONFERENCE

Communication: an essential component of Sanofi strategy

● An international campaign

● Three images: Vigilance, fake drugs exist - The patient, “a true victim” - The risk on Internet

● The 2 messages: the Risk related to fake medicines and Sanofi Commitment

● Air France campaign: “Beware of fake drugs”

| 11UNODC CONFERENCE

1. Improve overall knowledge related to fake medicines: improve data

collection, analysis, and draw conclusions for remedial action;

2. Encourage Member States to sign and ratify the Medicrime convention,

Council of Europe, and further determine legal assistance in this domain;

3. Ensure that fight against fake medicines is included as component of illicit

trafficking in UNODC regional programs of cooperation;

4. Foster public-private partnership to benefit every experience and exploit all

opportunities to eliminate or substantially reduce fake medicines as a

criminal activity.

Suggestions for Conference Outcome

| 12UNODC CONFERENCE

| 13UNODC CONFERENCE

SANOFI

Headquarters

54, rue La Boétie

75008 Paris, France

Tél. +33 (0)1 53 77 40 00

www.sanofi.com